Hrt Financial LP Alnylam Pharmaceuticals, Inc. Transaction History

Hrt Financial LP

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 13, 2024	BUY	$146.51 - $198.2 $6.14 Million - $8.31 Million	41,927 New	41,927 $6.27 Million
Q3 2023 Nov 13, 2023	BUY	$170.77 - $211.65 $356,909 - $442,348	2,090 New	2,090 $370,000
Q2 2022 Aug 12, 2022	SELL	$120.42 - $169.29 $233,373 - $328,084	-1,938 Closed	0 $0
Q1 2022 May 16, 2022	BUY	$127.18 - $173.91 $246,474 - $337,037	1,938 New	1,938 $316,000
Q4 2021 Feb 14, 2022	SELL	$159.56 - $209.29 $4.91 Million - $6.44 Million	-30,777 Closed	0 $0
Q3 2021 Nov 15, 2021	BUY	$169.75 - $207.73 $4.12 Million - $5.04 Million	24,261 Added 372.33%	30,777 $5.81 Million
Q2 2021 Aug 16, 2021	BUY	$128.63 - $176.89 $166,189 - $228,541	1,292 Added 24.73%	6,516 $1.1 Million
Q1 2021 May 17, 2021	BUY	$126.83 - $175.69 $429,826 - $595,413	3,389 Added 184.69%	5,224 $737,000
Q4 2020 Feb 16, 2021	SELL	$122.97 - $147.0 $2.53 Million - $3.03 Million	-20,589 Reduced 91.82%	1,835 $238,000
Q3 2020 Nov 13, 2020	BUY	$121.19 - $165.49 $2.72 Million - $3.71 Million	22,424 New	22,424 $3.26 Million
Q2 2019 Aug 14, 2019	SELL	$65.86 - $92.79 $498,955 - $702,977	-7,576 Closed	0 $0
Q1 2019 May 14, 2019	BUY	$72.76 - $93.45 $551,229 - $707,977	7,576 New	7,576 $707,000

650

109M

1.28M

1.23M

Ticker ALNY
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 123,028,000
Market Cap $33.4B
Description
Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. The company's pipeline of investigational RNAi therapeutics focuses on genetic medicines, cardio-metabolic diseases, hepatic infectious diseases, and central nervous system...

Get notified when there are updates to the investment portfolio of Hrt Financial LP, based on Form 13F filings with the SEC.

Stay updated on Hrt Financial LP with notifications on news.